The estimated Net Worth of Michael Raab is at least $12 million dollars as of 27 August 2024. Mr. Raab owns over 7,500 units of Ardelyx Inc stock worth over $7,268,274 and over the last 16 years he sold ARDX stock worth over $2,976,713. In addition, he makes $1,728,920 as President, Chief Executive Officer et Director at Ardelyx Inc.
Michael has made over 52 trades of the Ardelyx Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he sold 7,500 units of ARDX stock worth $46,650 on 27 August 2024.
The largest trade he's ever made was exercising 267,892 units of Ardelyx Inc stock on 3 August 2021 worth over $144,662. On average, Michael trades about 12,486 units every 39 days since 2008. As of 27 August 2024 he still owns at least 1,219,509 units of Ardelyx Inc stock.
You can see the complete history of Mr. Raab stock trades at the bottom of the page.
Michael G. Raab is President, Chief Executive Officer, Director of the Company. From 2002 to 2009, Mr. Raab was a partner at NEA, where he focused on investments in the biotechnology and pharmaceutical sectors. Prior to joining NEA, Mr. Raab spent 15 years in commercial and operating leadership roles in the biotech and pharmaceutical industries. He was Senior Vice President, Therapeutics and General Manager of the Renal Division at Genzyme Corporation, or Genzyme, a biotechnology company. Mr. Raab also spent two years with Genzyme’s diagnostic products and services division. Before Genzyme, Mr. Raab held business development and sales and marketing positions at Repligen Corporation, a life sciences company, and Bristol-Myers Corporation. Mr. Raab is currently a director of Amicus Therapeutics, Inc. (Nasdaq: FOLD). Mr. Raab currently serves as a member of the board of directors of the California Life Sciences Association, a non-profit trade association serving the life science industry in California, and as a member of the Emerging Companies Section Governing Board of the Biotechnology Innovation Organization. Mr. Raab received a B.A. from DePauw University.
As the President, Chief Executive Officer et Director of Ardelyx Inc, the total compensation of Michael Raab at Ardelyx Inc is $1,728,920. There are no executives at Ardelyx Inc getting paid more.
Michael Raab is 55, he's been the President, Chief Executive Officer et Director of Ardelyx Inc since 2009. There are 12 older and 6 younger executives at Ardelyx Inc. The oldest executive at Ardelyx Inc is Gordon Ringold, 69, who is the Independent Director.
Michael's mailing address filed with the SEC is C/O ARDELYX, INC., 400 FIFTH AVENUE, SUITE 210, WALTHAM, MA, 02451.
Over the last 10 years, insiders at Ardelyx Inc have traded over $37,312,621 worth of Ardelyx Inc stock and bought 85,247,838 units worth $820,614,871 . The most active insiders traders include Forest Baskett, Scott D Sandell et Anthony A. Jr. Florence. On average, Ardelyx Inc executives and independent directors trade stock every 12 days with the average trade being worth of $1,784,764. The most recent stock trade was executed by Michael Raab on 27 August 2024, trading 7,500 units of ARDX stock currently worth $46,650.
ardelyx is focused on enhancing the way people with renal diseases are treated by developing first-in-class medicines. ardelyx's renal pipeline includes the phase 3 development of tenapanor for the treatment of hyperphosphatemia in people with end-stage renal disease who are on dialysis and rdx013, a potassium secretagogue program for the potential treatment of high potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease. in addition, ardelyx has completed phase 3 development of tenapanor for the treatment of irritable bowel syndrome with constipation and anticipates submitting a new drug application to the u.s. food and drug administration for this indication in the second half of 2018. to efficiently bring its treatments to market, ardelyx is pursing strategic collaborations in the u.s. and other countries, including through established agreements with kyowa hakko kirin in japan, fosun pharma in china and knight therapeutics in canada.
Ardelyx Inc executives and other stock owners filed with the SEC include: